Skip to main content

Abbvie Value Stock - Dividend - Research Selection


ISIN: US00287Y1091, WKN: A1J84E

Market price date: 05.07.2022
Market price: 153,93 USD

Abbvie Fundamental data and company key figures of the share

Annual reports in USD
Key figures 01-03-2022
Cash flow
Net operating cash flow 22.777.000.000
Capital Expenditures -787.000.000
Free cash flow 21.990.000.640
Balance sheet
Total Equity 15.436.000.000
Liabilities & Shareholders equity 146.529.000.000
Income statement
Net income 11.542.000.000
Eps (diluted) 6,450
Diluted shares outstanding 1.765.130.000
Net sales/revenue

Fundamental ratios calculated on: 05-07-2022

Key figures 05-07-2022
Cash flow
P/C 11,92
P/FC 12,36
Balance sheet
Income statement
Div. Yield3,45%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization271.476.998.144,00 USD
CountryUnited States
IndicesMSCI World Index,Russell 3000,S&P 500
Raw Data SourceUS GAAP in Millionen USD
Stock Split

Description of the company

AbbVie Inc. (AbbVie) is a research-based pharmaceuticals company. The Company discovers, develops, and commercializes advanced therapies. AbbVie's portfolio of products include a line of adult and pediatric pharmaceuticals, which includes HUMIRA, metabolics/hormones products, virology products, endocrinology products, dyslipidemia products and other products. AbbVie products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, human immunodeficiency virus (HIV), cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease and complications associated with chronic kidney disease, among other indications. In October 2012, AbbVie initiated a comprehensive Phase III program for hepatitis C virus (HCV) genotype one.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


AbbVie : Statement of Changes in Beneficial Ownership (Form 4)

Ownership Submission FORM 4 Check this box if no longer... | July 5, 2022

'Minions' vs. 'Lightyear:' Here's why the silly yellow blobs beat Buzz at the box office

'Minions' and 'Toy Story' are among the most popular and profitable franchises for their respective studios — so why did "Minions" soar and "Lightyear" flop?

Q2 2022 Dividend Report

Passive income is up a solid +7% YOY. I've continued to selectively reinvest dividends as the market has pulled back. Click here for my Q2 2022 dividend report.

This Blockbuster Drug from AbbVie Is Closer to Another Major Indication

The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be its fifth indication in that market. This would be to treat patients with moderate-to-severe ulcerative colitis who had an inadequate response to conventional therapies or biologic agents. A decision for Rinvoq as a treatment for moderate-to-severe ulcerative colitis patients from the European Commission is expected in the third quarter of this year.

A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)

The most recent two hottest potatoes in the biotech arena are Aurinia and Seagen. See why we think AUPH should be on the long side and Merck in the short side.

7 Dividend Stocks to Buy in July 2022

Dividend stocks are only becoming more attractive as income becomes increasingly paramount. These seven equities pair dividends with safety.

Should You Consider Acquiring AbbVie (ABBV) Shares?

Carillon Tower Advisers, an investment management firm, published its “Carillon Clarivest Capital Appreciation Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. At the start of the quarter, the Carillon ClariVest Capital Appreciation Fund (the “Fund”), as compared to the Russell 1000® Growth Index, was most overweight in the […]

'Minions: The Rise of Gru' tops $108 million as parents flock back to cinemas, kids in tow

"Minions: The Rise of Gru" generated more than $108 million in ticket sales during its domestic opening weekend.

3 Stocks You Can Buy and Hold for Decades

Three little words can make you a lot of money over the long term: Buy and hold. Here's why they picked AbbVie (NYSE: ABBV), Bristol Myers Squibb (NYSE: BMY), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (AbbVie): Pharma giant AbbVie is currently defying gravity.

1H 2022 Portfolio Review - Avoiding A Personal Bear Market

My portfolio had a total return of -13.8% in the first half of 2022, beating the S&P index fund's total return of -20.0%.